Alzamend Neuro
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alzamend Neuro sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Alzamend Neuro: 4 sponsored US clinical trials, 1 recruiting.
Alzamend Neuro sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neurology, with 1 trials.
Upper-quartile sponsor footprint
Alzamend Neuro sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
NCT07540338
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
NCT06921590
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
NCT05834296
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
NCT05363293
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What is open in the Alzamend Neuro pipeline
1 recruiting of 4 indexed (25% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Neurology (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alzamend Neuro: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Alzamend Neuro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Alzamend Neuro page
4 registered trials is a research-attention snapshot, not an endorsement of Alzamend Neuro or any single study.
- 1 of Alzamend Neuro's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Neurology is the condition Alzamend Neuro studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neurology trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alzamend Neuro pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.